Kliničke studije za Leiomiom u državi Texas
7 studija za Leiomiom traži sudionike na lokacijama u državi Texas.
Gradovi u državi Texas
Službeni tekst studije (engleski)
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
- UT MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT06498648Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- M D Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 10. ruj 2026. · NCT04031677Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
- UT MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT05711615STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
- MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
- NEXT Dallas, Irving
- i još 2
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT06975293A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy
- MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 31. srp 2026. · NCT07633756Metastatic Leiomyosarcoma Biomarker Protocol
- MD Anderson, Houston
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 24. lip 2026. · NCT05653388A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
- MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 11. lip 2026. · NCT06789172Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.